Robert E. Hoffman - Aug 30, 2023 Form 4 Insider Report for Kintara Therapeutics, Inc. (KTRA)

Role
President, CEO and Interim CFO, Director
Signature
/s/ Robert E. Hoffman
Stock symbol
KTRA
Transactions as of
Aug 30, 2023
Transactions value $
$0
Form type
4
Date filed
9/1/2023, 06:00 PM
Previous filing
Jun 2, 2023
Next filing
Feb 7, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KTRA Options (Right to Buy) Award $0 +23.1K $0.00 23.1K Aug 30, 2023 Common Stock 23.1K $4.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 25% of the options vest on August 30, 2024, with the remaining shares vesting in 36 equal monthly installments commencing on September 30, 2024.